Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-LAST: Risperidone Long-Acting for Alcohol and Schizophrenia
NCT00130923Phase 4Completed
- Sponsor
- Dartmouth Health
- Start
- Sep 2005
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in alcohol use disorder (AUD), schizophrenia and schizoaffective disorder (2 arms), sponsored by Dartmouth Health. Primary endpoint: Change Over Time in Frequency of Heavy Drinking Days at 6 months. Started Sep 2005; status: completed.
02
Drugs
risperidone
03
Conditions
alcohol use disorder (AUD)schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00130923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130923.